miR-122 Inhibition in Human Liver Organoids: Construction, Characterization, and Disease Modeling
Source Sendi et al., 2018 · Wake Forest Institute of Regenerative Medicine / Wake Forest Baptist Medical Center · 10.1371/journal
Abstract
This protocol describes the construction and characterization of multicellular 3D human liver organoids containing primary hepatocytes (80%), Kupffer cells (10%), stellate cells (5%), and endothelial cells (5%) that remain viable and functional for 4+ weeks. The protocol includes methods for lentiviral transduction to inhibit miR-122 expression and comprehensive analysis of resulting inflammatory, fibrotic, and metabolic dysregulation as a model of non-alcoholic fatty liver disease (NAFLD).
Protocol overview
25 steps across 8 phases
- 1 Obtain and Thaw Cryopreserved Hepatic Cells
- 2 Prepare Cell Mixture
- 1 Form Organoids via Gravitational Aggregation
- 2 Transfer Organoids to Culture Medium (Hanging Drop Method)
- 3 Initialize Feeding Schedule (ULA Method)
- 1 Add Lentiviral Particles Immediately After Cell Mixing
- 1 Perform Medium Changes Every Other Day
- 1 Harvest and Pool Organoids
- 2 Assess Viability via Live/Dead Staining
- 3 Measure ATP Content for Viability
- 4 Extract Total RNA for qPCR
- 1 Fix Organoids
- 2 Embed in HistoGel and Paraffin
- 3 Cut and Prepare Histological Sections
- 4 Perform Standard Immunohistochemistry (IHC) on Sections
- 5 Perform Whole Mount Immunofluorescence
- 1 Synthesize cDNA
- 2 Prepare qPCR Master Mix
- 3 Load qPCR Arrays
- 4 Perform Thermal Cycling
- 5 Analyze Data
- 1 Transmission Electron Microscopy (TEM)
- 2 Measure Secreted Liver Function Markers
- 3 Assess Drug Metabolism Capacity
- 4 Perform Toxicity Assays (Optional)
Full SOP
Create a free account to access this protocol
Join OrganMatch to unlock step-by-step procedures, reagent concentrations, QC checklists, and downloadable batch record templates.
Create free accountAlready registered? Log in
Attribution
This SOP was authored by Organthis based on the published method in Sendi et al., 2018. The originating laboratory holds no rights in this SOP and has not endorsed it unless marked Verified.
This wording is awaiting legal review.
Something wrong with this entry? Report an issue with this protocol